Galera Therapeutics Competitors

Galera Therapeutics (NASDAQ:GRTX) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Galera Therapeutics and ORIC Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Galera Therapeutics and ORIC Pharmaceuticals, as provided by MarketBeat.

Galera Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 110.92%. ORIC Pharmaceuticals has a consensus price target of $43.7143, indicating a potential upside of 102.66%. Given Galera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Galera Therapeutics is more favorable than ORIC Pharmaceuticals.

Profitability

This table compares Galera Therapeutics and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

75.4% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. 19.3% of Galera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Galera Therapeutics beats ORIC Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Galera Therapeutics (NASDAQ:GRTX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Risk and Volatility

Galera Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.

Institutional and Insider Ownership

75.4% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. 19.3% of Galera Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Galera Therapeutics and Lexicon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Lexicon Pharmaceuticals has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Galera Therapeutics and Lexicon Pharmaceuticals, as provided by MarketBeat.

Galera Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 110.92%. Lexicon Pharmaceuticals has a consensus price target of $9.40, indicating a potential upside of 75.05%. Given Galera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Galera Therapeutics is more favorable than Lexicon Pharmaceuticals.

Profitability

This table compares Galera Therapeutics and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Esperion Therapeutics (NASDAQ:ESPR) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Esperion Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Institutional and Insider Ownership

75.4% of Galera Therapeutics shares are owned by institutional investors. 7.7% of Esperion Therapeutics shares are owned by insiders. Comparatively, 19.3% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Esperion Therapeutics and Galera Therapeutics' top-line revenue, earnings per share and valuation.

Galera Therapeutics has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Esperion Therapeutics and Galera Therapeutics, as provided by MarketBeat.com.

Esperion Therapeutics currently has a consensus target price of $50.60, indicating a potential upside of 87.76%. Galera Therapeutics has a consensus target price of $17.00, indicating a potential upside of 110.92%. Given Galera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Galera Therapeutics is more favorable than Esperion Therapeutics.

Profitability

This table compares Esperion Therapeutics and Galera Therapeutics' net margins, return on equity and return on assets.

Summary

Galera Therapeutics beats Esperion Therapeutics on 9 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Karyopharm Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Institutional and Insider Ownership

88.6% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Galera Therapeutics shares are owned by institutional investors. 13.3% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 19.3% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Galera Therapeutics' top-line revenue, earnings per share and valuation.

Galera Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Karyopharm Therapeutics and Galera Therapeutics, as provided by MarketBeat.com.

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Galera Therapeutics has a consensus target price of $17.00, indicating a potential upside of 110.92%. Given Karyopharm Therapeutics' higher possible upside, research analysts clearly believe Karyopharm Therapeutics is more favorable than Galera Therapeutics.

Profitability

This table compares Karyopharm Therapeutics and Galera Therapeutics' net margins, return on equity and return on assets.

Summary

Galera Therapeutics beats Karyopharm Therapeutics on 7 of the 13 factors compared between the two stocks.

Veru (NASDAQ:VERU) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Veru has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Earnings and Valuation

This table compares Veru and Galera Therapeutics' top-line revenue, earnings per share and valuation.

Veru has higher revenue and earnings than Galera Therapeutics. Veru is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

23.3% of Veru shares are owned by institutional investors. Comparatively, 75.4% of Galera Therapeutics shares are owned by institutional investors. 26.1% of Veru shares are owned by insiders. Comparatively, 19.3% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Veru and Galera Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Veru and Galera Therapeutics, as provided by MarketBeat.com.

Veru currently has a consensus target price of $19.25, indicating a potential upside of 85.99%. Galera Therapeutics has a consensus target price of $17.00, indicating a potential upside of 110.92%. Given Galera Therapeutics' higher possible upside, analysts clearly believe Galera Therapeutics is more favorable than Veru.

Summary

Veru beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Volatility & Risk

Ardelyx has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ardelyx and Galera Therapeutics' gross revenue, earnings per share and valuation.

Galera Therapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.9% of Ardelyx shares are held by institutional investors. Comparatively, 75.4% of Galera Therapeutics shares are held by institutional investors. 4.0% of Ardelyx shares are held by company insiders. Comparatively, 19.3% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ardelyx and Galera Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and price targets for Ardelyx and Galera Therapeutics, as provided by MarketBeat.

Ardelyx presently has a consensus target price of $14.00, indicating a potential upside of 88.17%. Galera Therapeutics has a consensus target price of $17.00, indicating a potential upside of 110.92%. Given Galera Therapeutics' higher possible upside, analysts plainly believe Galera Therapeutics is more favorable than Ardelyx.

Summary

Ardelyx beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks.